Recursion Pharmaceuticals, Inc.
RXRX · Mid Cap · NASDAQ · Healthcare · Biotechnology
Free AI brief
Get the full brief on RXRX
Free to track. No card required. Usually ready in 10-15 minutes.
Where RXRX sits today
Price, momentum, and the numbers behind the story.
RSI (14)
47.3Neutral
03070100
Stocksbrew score
46/100
See the full financial picture
Open the five-year record, valuation checks and Wall Street view behind these scores.
- ✓5 years of revenue, profit and cash flow
- ✓Valuation and balance-sheet checks
- ✓Business and geographic mix
- ✓Analyst targets and recommendation trend
Free for 3 days, then $9/mo. Cancel anytime.
What Wall Street thinks
Where the analysts and the crowd stand, and what it's worth to know first.
Analyst price targets
Current price
$3.46
Lowest
$4
Median target
$7
Highest
$10
LowHigh
The business, by the numbers
What it earns and where it earns it, what you're paying for the stock, and the risk sitting on the balance sheet.
RevenueTrend
✓ Good things about the company
Debt / equity
Favorable · 0.07 - strong leverage
0.07x
Current ratio
Strong · Good liquidity position
5.03x
⚠ Things to watch
Price / sales
Rich · Overpriced by revenue
42.62x
ROIC
Weak · Weak capital efficiency
-34.6%
ROE
Needs attention · Unfavorable
-56.6%
How it stacks up against its peers
RXRX against the names it's actually compared to.
| Company | Mkt cap | P/E | Rev growth | Score |
|---|---|---|---|---|
| $2.34B | - | -15.1% | 46 |
 | $10.02B | 19.1 | +19.7% | 78 |
 | $31.74B | 33.2 | +15.5% | 78 |
 | $4.23B | 12.7 | +13.5% | 78 |
 | $1.11T | 40.1 | +49.6% | 77 |
What is moving RXRX
Every story that touched the stock this week, newest first.